HIV viral blips — a detectable number, and a clear head.

There is a particular kind of silence that happens when you open a lab portal, scroll to the line that has said <20 or not detected for two years, and find a number sitting there instead. Forty-two. Eighty-eight. One hundred and thirty. The number is small. The feeling is not.

Take a breath. That number has a name, it has a large research literature behind it, and in most cases it has a boring ending. It's called a viral blip: after a period of viral suppression, an isolated detectable HIV RNA level that is followed by a return to suppression.1 The U.S. Department of Health and Human Services HIV clinical guidelines — the document your provider is almost certainly working from — say plainly that virologic blips "are not usually associated with subsequent virologic failure."1

This page is the long version of that reassurance, because reassurance without detail tends not to stick. We'll walk through what a blip technically is, the specific copies-per-milliliter numbers that mean different things, why laboratory tests wobble at the very bottom of their range, what happens to transmission risk (short answer: for a true blip, essentially nothing), how often blips actually happen, and the smaller set of situations where a detectable number genuinely is a signal worth chasing. We'll also talk about the part clinical guidelines don't cover: the anxiety, the forums, and how to have an honest conversation about missed doses without being made to feel small.

What a viral blip actually is

Start with vocabulary, because the words in this corner of HIV medicine are unusually precise and the precision is the whole point.

A viral load test measures copies of HIV's genetic material (RNA) per milliliter of blood plasma. Undetectable is not a fixed number — it's whatever the lower limit of detection is for the specific assay your lab runs, commonly fewer than 20 copies/mL, sometimes fewer than 40 or 50.3 Virologic suppression, in the DHHS guidelines, means a confirmed HIV RNA level below that lower limit of detection.1 HIV.gov uses a slightly broader public-health framing: viral suppression is having fewer than 200 copies of HIV per milliliter of blood.3

Against that backdrop, here is the formal definition of a blip, straight from the federal guidelines: "After virologic suppression, an isolated detectable HIV RNA level that is followed by a return to virologic suppression."1 Three components matter in that sentence:

• You were suppressed first. A blip is defined against a background of established suppression. A detectable result on your way down after starting treatment is not a blip — it's an expected part of the decline.
• It's isolated. One value. Not a trend, not a pair, not a staircase.
• It resolves. The next result comes back suppressed again.

That third component has an awkward consequence, and it's worth naming out loud because it explains why your clinic may sound frustratingly non-committal on the phone: a blip can only be confirmed in hindsight. As one review of the evidence puts it, one of the clinical challenges with blips is that "they can only be defined retrospectively once the VL has returned to a suppressed value."5 On the day you get the result, nobody — not you, not your provider, not the world's leading virologist — can tell you with certainty whether you are looking at a blip or the first data point of something else. What they can tell you is the probability, and the probability is heavily on the side of "blip."

Most research definitions put a blip somewhere under 200 copies/mL, though study protocols vary. The DHHS guidelines describe blips as transiently detectable at low levels, typically under a few hundred copies. IAS-USA has defined a blip as an isolated increase to under 1,000 copies/mL with a return to undetectable while on treatment. The British HIV Association uses a tighter definition — a single value between 50 and 200 copies/mL followed by an undetectable result.5 The variation across guidelines is not sloppiness; it reflects genuine scientific uncertainty about where random noise ends and biology begins.

The neighboring term you'll encounter is low-level viremia (LLV). In the DHHS framework, that's a confirmed HIV RNA level above the assay's lower limit of detection but still below 200 copies/mL.1 The distinction between a blip and LLV is not the size of the number. It's the pattern: a blip happens once and goes away; low-level viremia repeats.

Why blips happen

There is no single cause, and honesty about that is more useful than a tidy story. Researchers have spent more than two decades arguing about the mechanisms, and the current picture is that several different things produce the same result on a lab report.

1. Laboratory and assay variability

This is the most common and least dramatic explanation. Every biological assay has measurement noise, and HIV RNA assays are noisiest right at the bottom of their range — which is precisely where people on effective treatment live. When investigators diluted a World Health Organization HIV reference standard down to known low concentrations and ran it repeatedly on a widely used commercial assay, standards containing 36 copies/mL returned results of 50 copies/mL or higher in 66% of tests, and standards containing 18 copies/mL did so in 18% of tests.7 The virus in the tube never changed. The number on the report did.

2. Immune activation and intercurrent illness

Your immune system is not a quiet room. A cold, the flu, a sinus infection, a dental abscess, a herpes flare, or a recent vaccination can all transiently stir up immune activity, and that activity can nudge HIV RNA into detectable range for a short window. Mathematical modeling published in the Journal of Acquired Immune Deficiency Syndromes proposed exactly this: that transient activation of the immune system by infectious agents may explain episodes of viremia during otherwise suppressive treatment, with blips arising from target-cell activation and subsequent infection, or from activation of latently infected cells.6 aidsmap's plain-language explainer says the same thing for a general audience: blips may occur due to variations in laboratory processes, or having an infection like a cold or the flu.8

3. Release from the latent reservoir

HIV persists in long-lived resting cells even when treatment is working perfectly. Occasionally one of those cells wakes up and produces virus that shows up in plasma before the immune system and your medications clear it. Some studies suggest blips result from a release of virus from reservoirs in the body and are not an indication of ongoing viral replication.8 This is an important nuance: reservoir release is not treatment failure. Nothing has broken. A locked door opened for a moment and closed again.

4. Adherence gaps

Sometimes the explanation is the obvious one, and there is no shame in it. A few missed doses, a delayed refill, a week when the bottle stayed in a bag at someone else's apartment, a stretch of depression that made everything hard — these can produce a detectable result. Most blips likely represent normal biological fluctuation or laboratory artifact rather than inadequate adherence.5 But adherence review is a standard part of the workup precisely because it's fixable, and because catching a pattern early protects your future options.

5. Drug absorption and interactions

The IAS-USA panel specifically flags drug interactions in the evaluation of low-level viremia — including multivalent cations such as calcium, magnesium, iron, and zinc, which impair the absorption of integrase inhibitors. Which means an over-the-counter antacid, a calcium supplement, or a multivitamin taken at the wrong time relative to your HIV medication can meaningfully reduce drug levels in your blood. The panel's evaluation framework also includes assessing adherence (for example, through pharmacy refill records), considering intercurrent illness — where viremia should be transient rather than sustained — and, rarely, malabsorption.2

6. Coinfections and other inflammation

Hepatitis B or C, tuberculosis, syphilis, an active sexually transmitted infection, or any significant inflammatory illness can raise immune activation in a way that overlaps with mechanism two above. This is one reason your provider may order more than a repeat viral load — they may be checking whether something else is going on that happens to be showing up in the HIV number.

Blip vs. treatment failure — the actual numbers

This is the section most people are looking for. The numbers below are thresholds used in U.S. clinical guidelines, and knowing them turns an alarming result into a locatable one.

Put together, the mental model is a ladder rather than a switch. A detectable number under 200 that goes away is a blip. A number under 200 that keeps repeating is low-level viremia — worth watching closely, usually not worth changing medications over. A confirmed number at or above 200 is virologic failure by definition, and triggers a real workup. A number above 500 or 1,000 makes resistance testing both more informative and more urgent.

U=U and blips — what happens to transmission risk

For many people living with HIV, this is the real question hiding underneath the lab anxiety: did I put my partner at risk?

Here's the evidence. HIV.gov states that people living with HIV who take HIV medicine as prescribed and get and keep an undetectable viral load will not transmit HIV to their HIV-negative partners through sex — the principle known as Undetectable = Untransmittable, or U=U.3 That statement rests on some of the most robust prevention data in medicine.

HPTN 052 randomized 1,763 mixed-status couples to early versus delayed antiretroviral therapy. Final results published in the New England Journal of Medicine found early treatment was associated with a 93% lower risk of a genetically linked partner infection, and — the line that matters here — no linked infections were observed when HIV infection was stably suppressed by treatment in the index participant.9

PARTNER followed 782 serodifferent gay male couples through 1,593 eligible couple-years of follow-up, during which the HIV-negative partners reported 76,088 acts of condomless sex. The number of phylogenetically linked within-couple transmissions was zero. Critically for this article, the study's eligibility criterion for the partner living with HIV was a plasma HIV-1 RNA below 200 copies per mL at the most recent visit — not below 20, not "perfectly undetectable at every single draw."10

Opposites Attract enrolled 358 gay male serodiscordant couples across Australia, Brazil, and Thailand and recorded 16,800 acts of anal sex without condoms, including 12,447 acts where the partner living with HIV had an undetectable viral load and the HIV-negative partner was not taking PrEP. Linked transmissions: zero.11

Now apply that to a blip. A typical blip is a value like 60 or 150 copies/mL — below the 200 copies/mL threshold used in the transmission research. aidsmap's explainer draws the conclusion directly: a temporary viral load of 60 or 150 copies/mL "is still below 200 copies/ml and research has shown that someone with a viral load below this level is unable to pass on HIV during sex."8

Two honest caveats, because this site does not do false comfort:

• A blip is confirmed retrospectively. If your number is small and your next result returns to undetectable, the transmission picture never changed. If instead your viral load keeps climbing, the situation is different — and that's a genuine reason to get the repeat test done promptly rather than at your convenience.
• If viral load is truly detectable and rising, other prevention tools exist and work. HIV.gov's guidance is to protect an HIV-negative partner with methods such as PrEP for that partner until viral load is undetectable again, and to discuss PEP if there may have been an exposure.3 That's not a punishment. That's a toolkit.

What the research actually shows about how often blips happen

One of the most useful things to know is that you are not unusual. Blips are a normal feature of long-term successful HIV treatment, and the published prevalence estimates are strikingly wide — which itself tells a story.

A synthesis of the low-level viremia literature by the Ontario HIV Treatment Network found that blips, defined as an isolated HIV RNA of at least 50 copies/mL immediately preceded and followed by virologic suppression, have been reported in between 10% and 50% of people living with HIV, while low-level viremia — two or more consecutive results of at least 50 copies/mL — has an estimated prevalence of between 4% and 30%.5 Those ranges are enormous because the underlying definitions differ (50 vs. 200 vs. 1,000 copies/mL as the ceiling), the assays differ in sensitivity, and how often a cohort draws blood determines how many blips it catches at all.

The largest single dataset gives more concrete proportions. A retrospective analysis of 22,523 people receiving antiretroviral therapy in the multi-country EuResist database, published in Clinical Infectious Diseases, classified participants over 81,837 person-years of follow-up:

• 77% maintained virologic suppression throughout.
• 16% experienced viral blips — of whom 67% had only one blip during follow-up and 23% had two.
• 7% had low-level viremia in the 51–199 copies/mL range.4

So roughly one in six people in that cohort had at least one blip, and among those, two-thirds had exactly one — ever. That is the shape of the phenomenon: common, usually singular, usually over.

The same study is also the most-cited reason not to wave blips away entirely, and it deserves to be reported straight. Compared with sustained suppression, blips were associated with an adjusted hazard ratio of 1.7 for later virologic failure, and low-level viremia with an adjusted hazard ratio of 2.2.4 Relative risks like these are easy to misread, so here are the absolute numbers from the same paper: in the two years following a first detectable result, the risk of virologic failure was 5% among people with blips and 12% among people with low-level viremia.4

Read that carefully. A 5% two-year risk means 95% of people who had a blip did not go on to virologic failure within two years. aidsmap's coverage of the same study made the point that the vast majority of people who experienced a viral blip or low-level viraemia went on to re-suppress HIV and did not experience virologic failure.8 Both things are true at once: a blip is a modest statistical signal worth paying attention to, and it is overwhelmingly likely to end in re-suppression.

There is one more encouraging finding. In the EuResist analysis, among participants on initial integrase-inhibitor–based regimens — which is what most people starting treatment in the United States today are prescribed — there was no indication of increased virologic-failure risk related to blips or low-level viremia, although the authors noted this analysis was limited by a small number of failure events.4 Modern regimens are more forgiving than the ones most of this literature was built on.

When to actually worry

Most of this page is permission to relax. This section is the opposite, and it is short on purpose. There are specific patterns that deserve real attention, and knowing them is what makes the relaxing legitimate.

What your provider will actually do

Knowing the script in advance takes a surprising amount of the fear out of the phone call.

1. Repeat the viral load. This is the central move. For low-level results in a person who has been suppressed, the standard is to recheck rather than to react. When treatment has been modified or adherence supported after a result of 1,000 copies/mL or more, guidelines call for repeat HIV RNA testing in 4 to 8 weeks; after any regimen switch, HIV RNA testing should be performed within 4 to 8 weeks.1 Many clinics recheck a small blip on a somewhat shorter cycle — commonly two to four weeks — to shorten the waiting.
2. Review adherence. Expect questions about missed doses, refill timing, and life circumstances. The IAS-USA framework explicitly includes reviewing adherence, sometimes using objective data such as pharmacy refill records.2
3. Check for drug interactions. Bring everything: prescriptions, over-the-counter medications, supplements, antacids, vitamins, herbal products, and gender-affirming hormones. The interaction that matters is often something nobody thought to mention — calcium, magnesium, iron, or zinc taken close to an integrase inhibitor can impair absorption.2
4. Look for intercurrent illness. A recent infection or vaccination reframes the result. IAS-USA notes that with intercurrent illness, viremia should be transient rather than sustained.2
5. Not change your regimen — usually. This is worth repeating because it's the thing people most fear. Intermittent detection between 20 and 200 copies/mL and persistent low-level viremia at that level should not prompt changing treatment, per IAS-USA.2 DHHS agrees: people with confirmed low-level viremia below 200 copies/mL do not typically require a treatment change and should continue their current regimens with monitoring at least every three months.1
6. Order resistance testing only if the numbers justify it. If HIV RNA remains above 200 copies/mL after adherence support or a treatment change, genotypic resistance testing is recommended — with the caveat about low-level samples noted above.1

The adherence conversation — without shame

Here is a thing that happens in HIV clinics every day: someone gets a detectable result, they know exactly why (they ran out of pills for nine days in July), and they say nothing — because the last time they mentioned missed doses, a clinician sighed.

That silence is expensive. Not morally — practically. If your care team doesn't know about a nine-day gap, they may interpret a detectable result as possible resistance and order tests, or start considering regimen changes, when the real fix was a refill problem, a prior-authorization delay, a pharmacy that closed, or a month when depression made the bottle feel impossible to open.

Some framing that helps:

• Missed doses are a logistics problem, not a character problem. Pharmacy closures, insurance lapses, ADAP recertification paperwork, moving, incarceration, hospitalization, a lost bottle, a controlling partner, a chaotic month — these are the actual reasons people miss doses, and every one of them has a workaround that your case manager has seen before.
• Say the number, not the vibe. "I think I missed about six doses in the last two months, mostly weekends" is far more useful than "I've been pretty good." Precision helps your provider distinguish a blip from a pattern.
• You do not have to explain your life to justify a refill. "I need help staying on schedule — what tools do you have?" is a complete sentence. Clinics have pill boxes, blister packing, 90-day fills, text reminders, mail delivery, adherence counselors, and treatment adherence specialists.
• If the appointment felt shaming, that's information about the clinic, not about you. You are allowed to ask for a different provider, request a peer navigator, or bring someone with you.

It's also worth naming the language problem. Older clinical writing calls this "compliance," a word that frames medication as obedience. Adherence is a partnership between a person and a regimen that has to fit into an actual life. If the regimen doesn't fit the life — the dosing time is impossible with your work schedule, the pills upset your stomach, the food requirement doesn't work — then the regimen is the thing to change, and there are more options now than at any point in the history of this epidemic.

Assay differences and "false" detectable results

If you take one technical idea away from this page, make it this one: the number on your report is a measurement, and measurements have error bars that get proportionally wider as the quantity gets smaller.

The clearest demonstration comes from a study published in the journal AIDS, which set out to test whether low-level blips could be explained by assay variability alone. Investigators ran a WHO HIV-1 RNA reference standard at known low concentrations on a widely used commercial assay. Samples truly containing 36 copies/mL reported values of 50 copies/mL or higher in 66% of tests; samples containing 18 copies/mL did so in 18% of tests. Then they went to real specimens: for people on treatment who had unexpected viremia of 50–200 copies/mL after previously being under 50, retesting multiple aliquots of the same stored plasma found results under 50 copies/mL in nearly all cases — 14 of 15 aliquots, or 93%. When the team prospectively implemented repeat testing across four clinical trials for all samples with rebound between 50 and 200 copies/mL, 42% of those samples retested below 50 copies/mL on the same specimen.7

The authors' conclusion is the sentence to carry into your next appointment: in participants with a history of viral load suppression, unexpected low-level viremia may be due to assay variability rather than low drug adherence or true virologic failure — and retesting a stored aliquot of the same sample could save time, money, and anxiety for people and their providers.7

Several practical implications follow:

• Different assays are not interchangeable at the bottom. Platforms differ in lower limit of detection and in behavior near that limit. A result of "detected, less than 20" on one platform and "<40, not detected" on another can describe the same blood.
• Switching labs can create an apparent blip. If your clinic changed vendors, or you had blood drawn at a hospital instead of your usual clinic, a newly detectable result may be a change in instrument rather than a change in you. It's a fair question to ask.
• Sample handling matters. How long a tube sits, at what temperature, and how it's processed all affect low-level HIV RNA quantification. This is one more reason a single low number is a prompt to repeat, not a verdict.
• "Detected but not quantified" is its own category. Some reports say something like "target detected, less than 20 copies/mL." That means the assay saw a signal it could not put a number to. It is not a blip in the formal sense, and it is not virologic failure. It is the machine being honest about the edge of its own resolution.

None of this means blips are purely artifacts. The reservoir-release and immune-activation mechanisms are real, and low-level viremia that repeats has been associated with drug resistance and worse outcomes in multiple cohorts.45 It means that for a single small number in someone who has been reliably suppressed, measurement noise is a leading explanation, and a repeat test — not a regimen change — is the right response.

Living with the anxiety

Clinical guidelines are silent on the part that actually keeps people up. So let's say it directly: for many people living with HIV, the viral load result is not a lab value. It is a report card, a referendum, and a threat assessment, delivered by a patient portal at 9:40 on a Tuesday night with no human attached.

That reaction is not irrational. Undetectable status is genuinely load-bearing — it carries your health, your sense of safety with partners, sometimes your ability to describe yourself as someone who has this handled. A detectable number can feel like all of that coming loose at once. Naming the mechanism helps: what you are experiencing is not a response to 91 copies/mL, it is a stress response to a symbol. Things that help, from people who have been through this:

• Put the number in a sentence with its context. "One result of 91, after 14 undetectable results, on a regimen I take every day." A number alone is frightening. A number in a series is data.
• Set the calendar reminder immediately. Book the repeat test the same day you see the result. Uncertainty with an end date is much easier to carry than uncertainty without one.
• Be careful with forums at 2 a.m. Community spaces are genuinely valuable — POZ, TheBody, and Positively Aware exist because people living with HIV needed each other's voices, and they still do. But the loudest threads in any HIV forum tend to be the worst-case ones, because people whose repeat test came back undetectable stop posting and go live their lives. Selection bias is not the same thing as prognosis.
• Prefer sources that show their numbers. If a page tells you what a blip is without telling you the thresholds, the prevalence, or where the data came from, close the tab. This page has fifteen references at the bottom for exactly that reason.
• Tell one person. A partner, a friend, a peer navigator, a support group. Carrying a scary lab result alone for three weeks is much harder than carrying it with someone.
• Get support that fits the size of the problem. If lab anxiety is affecting your sleep, appetite, or ability to attend appointments, that is worth a conversation with your care team. Ryan White programs fund mental health services and peer support for exactly this reason.

One more reframe. The fact that a blip is detectable at all is a consequence of how good HIV medicine has become. Assays now reach down to 20 copies/mL and below. Twenty years ago, most of the numbers that trigger panic today would have simply been reported as undetectable and nobody would have thought about them. As the DHHS guidelines note, the more sensitive real-time PCR assays in current use detect viremia at low thresholds more frequently than older platforms did.1 You are not sicker than people were in 2005. The microscope got better.

Florida: monitoring standards, ADAP, and what you're entitled to

If you get your HIV care in Florida through a Ryan White–funded program, your viral load monitoring is not left to chance. It is written into the service standards your clinic is contracted to follow.

The Miami-Dade County Ryan White Program's minimum primary medical care standards — which local funded practitioners are required by contract to follow, at minimum, alongside Public Health Service guidelines — state that "all clients, regardless of viral load levels, must have viral load tests every 6 months per the DHHS/HRSA standards." The same standards spell out the monitoring cadence in detail: viral load at entry into care, at treatment initiation or modification, then 4 to 8 weeks after initiation or modification if HIV RNA is still detectable, repeating every 4 to 8 weeks until viral load is suppressed below 50 copies/mL, and thereafter every 3 to 6 months. They also specify that more frequent monitoring may be considered for people having difficulties with adherence or at risk for nonadherence, while adherent clients with consistently suppressed viral load and stable immunologic status for more than a year can extend to 6-month intervals.14

Why this matters if you're the person staring at a blip: the repeat test you need is a covered, expected, standard part of your care. You are not asking for a favor. Monitoring after a detectable result is exactly what the standards describe.

On the medication side, Florida's AIDS Drug Assistance Program (ADAP) is the largest program funded through Ryan White Part B in the state and operates as a statewide program covering formulary medications and, in some cases, out-of-pocket costs such as deductibles, co-pays, or coinsurance. Enrollment requires an initial eligibility application, and — the detail that trips people up — recertification into the program every six months.15

A few more Florida practicalities:

• Ask which lab your clinic uses. Florida county health departments, Ryan White clinics, hospital systems, and private infectious disease practices don't all use the same assay platform. If your care moves between them — common in a state where people relocate between counties — a change in reported detection floor can look like a change in your virus.
• Your case manager is a resource for the anxious weeks. Medical case management and peer support are Ryan White core service categories. If you're waiting three weeks for a repeat test and struggling, ask.
• Hurricane season is an adherence hazard. Evacuations, pharmacy closures, and power outages have all interrupted medication access in Florida. An emergency supply and a plan for where you'd refill out of county is legitimate blip prevention.

The bottom line

A single small detectable viral load, after a stretch of undetectable results, in a person taking their medication, is most likely a blip. Federal guidelines say blips are not usually associated with subsequent virologic failure.1 The IAS-USA panel says intermittent detection in that range should not prompt a treatment change.2 HIV.gov says it in the plainest words available: HIV may occasionally be detected by a lab test even if a person is taking their HIV medicine as prescribed — this is known as a blip, and it doesn't necessarily mean that treatment isn't working.3

Your job in the meantime is small and specific. Keep taking your medication exactly as prescribed. Get the repeat test on the schedule your clinic sets. Tell your team about any illness, vaccination, supplement, or refill gap near the draw date. Watch the trend rather than the point. And if the repeat comes back undetectable — which is the most likely outcome by a wide margin — let yourself actually put it down.

One number is not a verdict. It's a data point, and you have a whole graph.